Researchers conducted a retrospective cohort study of 34,248 women diagnosed with locoregional breast cancer who received ...
Clinical Trials Arena on MSN4d
Innovent Biologics doses first subject in trial of ovarian cancer therapyInnovent Biologics has dosed the first subject in the randomised Phase III HeriCare-Ovarian01 trial of IBI354 for treating ...
Researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen ...
Results provide proof-of-concept that ERK pathway reactivation might be an effective, biologically based therapy to prevent anthrax-induced lethality.
Radiopharm Theranostic (RADX)s announced a poster presentation at EMIM 20251, with findings that support the clinical utility of imaging and ...
Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.
News-Medical.Net on MSN10d
Moffitt researchers discover new vaccine strategy for treating specific type of breast cancerMoffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer.
Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback